Microbiome Connect : Human - USA 2020 | Kisaco Research

Designing Microbiome-Modulating Therapeutics and Diagnostics for the Treatment of Neurological, Cancer, Metabolic and Gastro-Intestinal Indications.

Register
Boston, USA
3-4 June, 2020

“This event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science. Kisaco has gone out of their way to include speakers and perspectives not found elsewhere. I look forward to attending again.”

KC Microbiome Communications Group

Why Attend

The gut microbiome is becoming an increasingly important druggable target for pharma companies through a range of modalities from FMT to small molecule and even phage. 2020 looks set to be a pivotal year for the microbiome industry with a handful of companies (including Seres, Rebiotix and Finch Therapeutics) set to release ground-breaking phase 3 clinical data. We’re a step away from market approval, but there’s still so much to learn…

Major advances in shotgun metagenomic sequencing and computational biology allow us to see what’s going on at a strain-specific and metabolomic level of detail. Elucidating the key metabolites and mechanisms of action in both extra-intestinal and intestinal indications is a key objective in 2020/2021 and is a cornerstone of the discussion at Microbiome Connect: Human. 

Join key opinion leaders and 50+ expert speakers across three dedicated tracks of content to examine the latest preclinical and clinical data in extra-intestinal and intestinal indications. This is your opportunity to find out how others plan on translating gut-microbiome research into therapeutics that have the power to treat Oncological, Neurological, Gastro-Intestinal & Metabolic diseases.

Previously known as North American Microbiome Congress, Microbiome Connect: Human USA is all about connecting leading academics and biotech companies presenting preclinical and clinical data, to network, educate and share knowledge. 

200+
delegates
3
distinct streams
50+
leading top speakers
14th
event in the global series

What's new for 2020

  1. Deep dive into the microbiome’s mechanistic and metabolomic role in Neurological, Oncological, Gastro-Intestinal & Metabolic indications with three distinct scientific streams of the latest pre-clinical and clinical data.

  2. Assess how leading biotech companies and academics are designing a range of therapeutic microbiome-modulating modalities from small-molecule and Phage to rationally designed live bio-therapeutics and FMT. 

  3. Meet your next commercial partner and learn exactly what Pharma and VCs are looking for in terms of pre-clinical and clinical data to finance academic spin-outs and later-stage clinical trials.

Speakers

 

Johan van Hylckama Vlieg

CSO
Kaleido

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.

Johan van Hylckama Vlieg

CSO
Kaleido

Johan van Hylckama Vlieg

CSO
Kaleido

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.

 

Dan Couto

COO
Vedanta

Dan Couto

COO
Vedanta

Dan Couto

COO
Vedanta
 

Jessica Schneider

Director, Gastroenterology Drug Discovery, Microbiome Research
Takeda

Jessica Schneider

Director, Gastroenterology Drug Discovery, Microbiome Research
Takeda

Jessica Schneider

Director, Gastroenterology Drug Discovery, Microbiome Research
Takeda
 

Emeran Mayer

Professor
UCLA

Dr. Emeran Mayer is a Professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA, Executive Director of the Oppenheimer Center for Neurobiology of Stress, and Co-director of the CURE: Digestive Diseases Research Center at UCLA.

Emeran Mayer

Professor
UCLA

Emeran Mayer

Professor
UCLA

Dr. Emeran Mayer is a Professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA, Executive Director of the Oppenheimer Center for Neurobiology of Stress, and Co-director of the CURE: Digestive Diseases Research Center at UCLA. He is a world renowned gastroenterologist and neuroscientist with 30 years of experience in the study of clinical and neurobiological aspects of how the digestive system and the nervous system interact in health and disease, and his work has been continuously supported by the National Institutes of Health (NIH). He is currently principal investigator on 4 NIH grants including a center grant from ORWH/NIDDK on sex differences in brain gut interactions, a consortium grant by NIDDK on pelvic pain syndromes, a RO1 grant on the effects of cognitive behavioral therapy on brain signatures in IBS and a ROI grant on brain gut microbiome interactions in inflammatory and functional GI disorders (both from NIDDK). He has published over 320 peer-reviewed articles (average H index 90), including 100 chapters and reviews, co-edited four books, and organized several interdisciplinary symposia in the area of visceral pain and mind body interactions. His current research focus is on the role of the gut microbiota in modulating brain gut interactions, and their role in emotion regulation, chronic visceral pain and obesity.

 

Dr Michael Zasloff

CSO & Co-Founder
Enterin

Michael Zasloff (MD, PhD) is the Chief Science Officer and medical guru behind illumai and our patent-pending XO-70® science. A firm believer that every day is a good day to discover a better solution, Dr. Zasloff has dedicated his career to understanding the self-healing properties of the skin. It was through this research that he discovered a vital need for better cleansing options for the hair, skin and scalp. And with illumai, that is exactly what he did.

Dr Michael Zasloff

CSO & Co-Founder
Enterin

Dr Michael Zasloff

CSO & Co-Founder
Enterin

Michael Zasloff (MD, PhD) is the Chief Science Officer and medical guru behind illumai and our patent-pending XO-70® science. A firm believer that every day is a good day to discover a better solution, Dr. Zasloff has dedicated his career to understanding the self-healing properties of the skin. It was through this research that he discovered a vital need for better cleansing options for the hair, skin and scalp. And with illumai, that is exactly what he did.

For over 25 years, Dr. Zasloff has studied the mechanisms behind illumai’s proprietary cleansing ingredient XO-70®. But it was only recently that he was able to distill the multiple beneficial aspects of this cleansing agent into a format that was highly compatible with hair, and that would produce such luxurious, rich results. With this discovery, illumai was born – a prestigious line of products that is revolutionizing haircare by changing how we approach actually cleansing the hair and scalp. And, we are doing it all without the need for sodium lauryl sulfate, organosulfates, preservatives, parabens or silicones, or asking you to sacrifice your health to look and feel absolutely beautiful.

“We all believe that natural beauty is the best kind of beauty, and with Illumai, your hair finally has a chance to shine with the same radiance, luminosity and strength as when you were a child. To ensure these results, I personally demanded that every product Illumai creates be 100% free of all sulfates because I know first-hand how dangerous they are, and that they aren't necessary ingredients in our personal care products. With illumai, I hope the health and beauty of your hair will be nothing less than remarkable.”

– Dr. Michael Zasloff

 

Christopher Missling

Anavex

Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for neurodegenerative and neurodevelopmental diseases, like Alzheimer’s disease, and Parkinson’s disease, as well as, Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms. Dr.

Christopher Missling

Anavex

Christopher Missling

Anavex

Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for neurodegenerative and neurodevelopmental diseases, like Alzheimer’s disease, and Parkinson’s disease, as well as, Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.

 

Anna Williamson

Senior Director Oncology Business & Head of UK Business Development
Roche/Genentech

Anna Williamson is a member of Roche and Genentech’s partnering group.  Anna is based in Cambridge, UK and is responsible for sourcing and evaluating new collaboration opportunities and executing strategic alliances in all areas of interest to Roche and Genentech, with an increasing focus on UK/European companies.  Anna joined Genentech in San Francisco in 2004 and moved to Cambridge in 2017 to establish a partnering presence in the UK.

Anna Williamson

Senior Director Oncology Business & Head of UK Business Development
Roche/Genentech

Anna Williamson

Senior Director Oncology Business & Head of UK Business Development
Roche/Genentech

Anna Williamson is a member of Roche and Genentech’s partnering group.  Anna is based in Cambridge, UK and is responsible for sourcing and evaluating new collaboration opportunities and executing strategic alliances in all areas of interest to Roche and Genentech, with an increasing focus on UK/European companies.  Anna joined Genentech in San Francisco in 2004 and moved to Cambridge in 2017 to establish a partnering presence in the UK. Prior to joining Genentech, Anna worked for the University of California Office of Technology Transfer where she was a member of the life-sciences team, responsible for managing and out-licensing a portfolio of life sciences inventions from multiple UC campuses.  Anna holds a BA in Natural Sciences (Neuroscience) and a PhD in Neuroscience, both from the University of Cambridge and carried out post-doctoral research at the University of Colorado and UCSF.

 

Glennda Smithson

Director, Translational Biomarker Research
Takeda

Glennda Smithson

Director, Translational Biomarker Research
Takeda

Glennda Smithson

Director, Translational Biomarker Research
Takeda
 

Lothar Steidler

CTO
Actobio

Lothar Steidler

CTO
Actobio

Lothar Steidler

CTO
Actobio
 

Jack Egelund Madsen

Chief Business Officer
Clinical Microbiomics

Jack Egelund Madsen

Chief Business Officer
Clinical Microbiomics

Jack Egelund Madsen

Chief Business Officer
Clinical Microbiomics
 

Julius Goepp

CEO
Scaled Microbiomics

Julius Goepp

CEO
Scaled Microbiomics

Julius Goepp

CEO
Scaled Microbiomics
 

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx
 

Sonia Timberlake

VP Research, Head of Data Science
Finch Therapeutics

Sonia Timberlake

VP Research, Head of Data Science
Finch Therapeutics

Sonia Timberlake

VP Research, Head of Data Science
Finch Therapeutics
 

Giulio Pasinetti

Professor
Ichan School of Medicine

Giulio Pasinetti

Professor
Ichan School of Medicine

Giulio Pasinetti

Professor
Ichan School of Medicine
 

Frank Middleton

Associate Professor
Upstate Medical School

Frank Middleton

Associate Professor
Upstate Medical School

Frank Middleton

Associate Professor
Upstate Medical School
 

Matt Henn

CSO
Seres

Matt Henn

CSO
Seres

Matt Henn

CSO
Seres
 

Sudha Biddinger

Associate Professor
Harvard Medical School

Sudha Biddinger

Associate Professor
Harvard Medical School

Sudha Biddinger

Associate Professor
Harvard Medical School
 

Ellen Li

Professor
Stony Brook University

Ellen Li

Professor
Stony Brook University

Ellen Li

Professor
Stony Brook University
 

Sridevi Devraj

Professor
Baylor College of Medicine

Sridevi Devraj

Professor
Baylor College of Medicine

Sridevi Devraj

Professor
Baylor College of Medicine
 

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America.

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America. Grégory also has experience managing IP, business development and general management.  He is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he has driven the development of several pharmaceutical products from the laboratory through to market authorisation. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations, so far has raised over 10M€ in a mixture of grant and VC funding and begins human clinical trials this year.

 

Serguei Fetissov

Professor
Rouen University

Serguei Fetissov

Professor
Rouen University

Serguei Fetissov

Professor
Rouen University
 

Dan Couto

COO
Vedanta

Dan Couto

COO
Vedanta

Dan Couto

COO
Vedanta
 

John Aunins

CTO
Seres

John Aunins

CTO
Seres

John Aunins

CTO
Seres
 

Scott Plevy

CSO
Synlogic

Scott Plevy

CSO
Synlogic

Scott Plevy

CSO
Synlogic
 

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a trans-national group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D. Mike is highly experienced in the biotech translation and commercialisation, currently serving as a Non-Exec Director of the life-sciences charity LifeArc, and previously as Translational Adviser in Biomedicine at Imperial College, Venture Partner to UK Innovation and Science Seed Fund, and committee member on the MRC’s Developmental Pathway Funding Scheme for translational academic research. Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and is a Fellow of the Royal Society of Biology.

 

Bharat Dixit

VP, Biopharmaceutical Development & Manufacturing
ClearB Therapeutics

Bharat Dixit

VP, Biopharmaceutical Development & Manufacturing
ClearB Therapeutics

Bharat Dixit

VP, Biopharmaceutical Development & Manufacturing
ClearB Therapeutics
 

Lucy Yanckello

PhD Student
University of Kentucky

Lucy Yanckello

PhD Student
University of Kentucky

Lucy Yanckello

PhD Student
University of Kentucky
 

Mark Smith

CEO
Finch Therapuetics

Mark Smith

CEO
Finch Therapuetics

Mark Smith

CEO
Finch Therapuetics
 

Rodolphe Clerval

CBO
Enterome

Rodolphe Clerval

CBO
Enterome

Rodolphe Clerval

CBO
Enterome
 

Imke Mulder

Research Director
4D Pharma

Imke Mulder

Research Director
4D Pharma

Imke Mulder

Research Director
4D Pharma
 

Maya Kahan-Hanum

Project Manager
BiomX

Maya Kahan-Hanum

Project Manager
BiomX

Maya Kahan-Hanum

Project Manager
BiomX
 

Mingyang Song

Associate Professor
Harvard T.H Chan School of Public Health

Mingyang Song

Associate Professor
Harvard T.H Chan School of Public Health

Mingyang Song

Associate Professor
Harvard T.H Chan School of Public Health
 

Fyza Shaikh

Postdoctoral Fellow
The Johns Hopkins Hospital

Fyza Shaikh

Postdoctoral Fellow
The Johns Hopkins Hospital

Fyza Shaikh

Postdoctoral Fellow
The Johns Hopkins Hospital
 

Torsten Madsen

CMO
Axial Therapeutics

Torsten Madsen

CMO
Axial Therapeutics

Torsten Madsen

CMO
Axial Therapeutics
 

Isabelle De Cremoux

CEO
Seventure Partners

Isabelle De Cremoux

CEO
Seventure Partners

Isabelle De Cremoux

CEO
Seventure Partners
 

Denise Kelly

Investment Advisor
Seventure

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field.

Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome.

Denise Kelly

Investment Advisor
Seventure

Denise Kelly

Investment Advisor
Seventure

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field.

Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome.

Denise is currently based in Aberdeen, Scotland. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies.

 

Xue Liang

Senior Scientist
Merck

Xue Liang

Senior Scientist
Merck

Xue Liang

Senior Scientist
Merck
 

Diwakar Davar

Assistant Professor
University of Pittsburgh, School of Medicine

Diwakar Davar

Assistant Professor
University of Pittsburgh, School of Medicine

Diwakar Davar

Assistant Professor
University of Pittsburgh, School of Medicine
 

Nicole McKnight

COO
Amabiotics

Nicole McKnight

COO
Amabiotics

Nicole McKnight

COO
Amabiotics
 

Jason Norman

Associate Director, System Biology
Vedanta

Jason Norman

Associate Director, System Biology
Vedanta

Jason Norman

Associate Director, System Biology
Vedanta
 

Ben Bradley

Head of Partnerships & Licensing
CHAIN Biotech

Ben Bradley

Head of Partnerships & Licensing
CHAIN Biotech

Ben Bradley

Head of Partnerships & Licensing
CHAIN Biotech
 

Meenakshi Roa

Principal Investigator
Harvard Medical School

Meenakshi Roa

Principal Investigator
Harvard Medical School

Meenakshi Roa

Principal Investigator
Harvard Medical School
 

Romain Dailiere

CEO
Everimmune

Romain Dailiere

CEO
Everimmune

Romain Dailiere

CEO
Everimmune
 

Nikole Kimes

Founder and CSO
Siolta Therapeutics

Talk to me about… your research

Nikole Kimes

Founder and CSO
Siolta Therapeutics

Nikole Kimes

Founder and CSO
Siolta Therapeutics

Talk to me about… your research

Our mission at Siolta Therapeutics is to transform the therapeutic landscape of inflammatory diseases, such as asthma, through the power of the microbiome. As the lead executive driving Siolta’s early-stage development, I head a talented team of scientists, blending microbiology, immunology, and bioinformatics expertise to leverage microbiome data for the improvement of patient stratification and development of targeted microbial therapeutics. We are developing FDA-approved live biotherapeutics, as well as companion diagnostics, aimed not only at treating disease but also preventing disease, starting with asthma.

Talk to me about…something people may not know about you

My two professional passions have always been environmental systems and health. I have spent the entirety of my career exploring the relationship between these two concepts, from my time in the Solomon Islands as a Peace Corps Volunteer to my PhD work in marine ecosystems impacted by environmental alterations.

 

Lee Jones

CEO
Rebiotix

Lee Jones

CEO
Rebiotix

Lee Jones

CEO
Rebiotix
 

Ken Blount

Chief Scientific Officer
Rebiotix

Ken Blount, PhD, is the Chief Scientific Officer at Rebiotix, a clinical-stage company developing transformational Microbiome Restoration Therapeutics (MRT). Ken has directed innovative R&D teams at multiple companies and academic institutions, including as the co-founder of BioRelix, a venture-backed company that developed new antibiotics for novel mRNA target classes. His scientific expertise includes microbiome and antibiotic drug development, translational medical oncology, and RNA biology.

Ken Blount

Chief Scientific Officer
Rebiotix

Ken Blount

Chief Scientific Officer
Rebiotix

Ken Blount, PhD, is the Chief Scientific Officer at Rebiotix, a clinical-stage company developing transformational Microbiome Restoration Therapeutics (MRT). Ken has directed innovative R&D teams at multiple companies and academic institutions, including as the co-founder of BioRelix, a venture-backed company that developed new antibiotics for novel mRNA target classes. His scientific expertise includes microbiome and antibiotic drug development, translational medical oncology, and RNA biology. At Rebiotix, Ken leads the evolution of new analytic tools to demonstrate microbiome restoration for Rebiotix’ novel MRT portfolio, and he is heading the expansion of Rebiotix MRT platform to new therapeutic areas.

 

Raja Dhir

Co-Founder and Co-CEO
Seed, Inc

Raja Dhir

Co-Founder and Co-CEO
Seed, Inc

Raja Dhir

Co-Founder and Co-CEO
Seed, Inc

Who Will Be There

30%
Biotechs
30%
Academics
25%
Big Pharma
10%
Clinicians
5%
Multinational Food Companies

Biotechs

Academics

Big Pharma

Clinicians

Multinational Food Companies

Submit your poster

Looking to showcase your recent work to the microbiome community?

Our dedicated poster area is the perfect way to get your research noticed and further involve yourself in the congress. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).

At the Congress, your presentation will be displayed in a dedicated poster area which can be viewed during the networking break.

CLICK HERE TO MAKE A SUBMISSION

Associate Event Partner

Senior Event Partner

Event Partner

Media Partner

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Agenda

Fill in your details to download our full agenda which showcases the speakers as well as key topics we will be covering in Microbiome Connect: Human USA.

What you can expect from the 2020 Congress:

  • 200+ Academic and Industry Leaders Onsite
  • 50+ Thought Leaders on the Speaker Faculty
  • 3 Distinct Streams

Download our Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket prices increase in

Wednesday, January 8, 2020 to Friday, March 6, 2020
Academics, Clinicians, Post-Doctural Researchers
$799
Super Early Bird available through March 6 2020
Main 2 Day Conference - All Sessions
Wednesday, January 8, 2020 to Friday, March 6, 2020
Biotech
$899
Super Early Bird available through March 6 2020
Main 2 Day Conference - All Sessions
Wednesday, January 8, 2020 to Friday, March 6, 2020
Pharma & Multinational
$1399
Super Early Bird available through March 6 2020
Main 2 Day Conference - All Sessions
Wednesday, January 8, 2020 to Friday, March 6, 2020
Service Providers
$1,899
Super Early Bird available through March 6 2020
Main 2 Day Conference - All Sessions
Preparing registration...

Venue

Boston, USA

The congress will take place in Boston, the venue is to be confirmed.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

Animal Microbiome USA 2019

Microbiome Congress 2019